Top Banner
Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco
18

Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Dec 22, 2015

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Methadone inOpioid Addiction

Methadone inOpioid Addiction

David Kan, M.D.

University of CaliforniaSan Francisco

VA Medical CenterSan Francisco

Page 2: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Opium in San Francisco

Page 3: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

OPIATES

Page 4: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Estimated Total Number of Heroin/Morphine-RelatedHospital Emergency Department Visits by Year (DAWN, 2002)

1988 1989 1990 1991 1992 1993 1994 1995 1996 199730,000

40,000

50,000

60,000

70,000

80,000

1999 2000 2001

90,000

95,000

1998

Page 5: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Heroin 101 New production in South America High purity/potency (smokeable) Detoxification is of limited long-term

efficacy Most effective treatment for chronic

users is Methadone Maintenance Medications

Methadone Opioid Agonist Therapy Buprenorphine Partial Agonist Therapy Naltrexone Opioid Blockade

Page 6: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Heroin Short acting opiate Immediate effects:

Heroin crosses the blood-brain barrier Heroin is converted to morphine and binds

rapidly to opioid receptors Causes euphoria Pain relief Flushing of the skin Dry mouth Heavy feeling in the extremities

Page 7: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Heroin

After initial effects: Drowsy for several hours. Clouded mental function Slowed cardiac function Slowed breathing

Death by respiratory failure (overdose)

Page 8: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

40 Year Natural Historyof Heroin Addiction

The natural history of narcotics addiction among a male sample (N = 581). From: Yih-Ing, et. al., 2001. A 33-Year Follow-up of Narcotics Addicts. Archives of General Psychiatry, 58:503-508)

48%

Page 9: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Opiate Addiction: Medications

Detoxification Opioid Substitution

Methadone (Agonist) [Illegal on outpatient basis]

Buprenorphine (Partial Agonist) [Requires special DEA license]

Non-Opioid Symptom Relief Clonidine / Lofexadine / Anti-spasmodic, anti-

diarrheals / NSAIDS for bone pain and myalgia Sleep meds

95%+ poor outcome

Page 10: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Naltrexone:Efficacy vs. Effectiveness

High Efficacy: An almost perfect, long-acting blocker of

opiates Limited Effectiveness:

Most effective in monitored treatment of medical or other professionals, executives, and individuals on probation

Poor compliance in heroin-using population

Poor treatment retention

Page 11: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Methadone Maintenance

The Gold Standard

Page 12: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Opiate Addiction: Maintenance

Methadone Dole & Nyswander’s opioid deficiency theory

(1964). Daily Dosing, Blocking dose usually > 60 mg qd

Buprenorphine (formulated with or without naloxone) Partial Agonist (high opiate receptor avidity but

low innate activity) Daily dosing, 2-32 mg qd

Page 13: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Impact of MMT on IV Drug Use for 388 Male MMT Patients in 6 Programs

PE

RC

EN

T I

V U

SE

RS

0

100

LA

ST

AD

DIC

TIO

N P

ER

IOD

AD

MIS

SIO

N

100%

81.4%

Pre- | 1st Year | 2nd Year | 3rd Year | 4th

*

*

63.3%

41.7%

28.9%

Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance Treatment, 1991

Page 14: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Recent Heroin Use by Current Methadone Dose

0

20

40

60

80

100

120

0 10 20 30 40 50 60 70 80 90 100

Current Methadone Dose mg/day

% H

ero

in U

se

J. C. Ball, November 18, 1988Opioid Agonist Treatment of Addiction - Payte - 1998

Page 15: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Relapse to IV drug use after MMT105 male patients who left treatment

28.9

45.5

57.6

72.2

82.1

0

20

40

60

80

100

IN 1 to 3 4 to 6 7 to 9 10 to 12

Pe

rce

nt

IV U

se

rs

Months Since Stopping Treatment

Opioid Agonist Treatment of Addiction - Payte - 1998

Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance Treatment, 1991

Page 16: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Crime among 491 patients before and during MMT at 6 programs

0

50

100

150

200

250

300

A B C D E F

Before TX

During TX

Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance Treatment, 1991

Cri

me

Day

s P

er Y

ear

Page 17: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Death Rates in Treated and Untreated Addicts

0

1

2

3

4

5

6

7

8

MMT VOL DC TX INVOL DC TX UNTREATED

OBSERVEDEXPECTED

% Annual Death Rates

Slide data courtesy of Frank Vocci, MD, NIDA – Reference: Grondblah, L. et al. Acta Pschiatr Scand, P. 223-227, 1990

Page 18: Methadone in Opioid Addiction David Kan, M.D. University of California San Francisco VA Medical Center San Francisco.

Summary of Methadone Maintenance Outcomes

Gold-Standard for Opioid Treatment One of the most over-proven treatments in entire

psychiatry and drug abuse literature

Detoxification methods succeed only < 3% of the time.

Outcomes Measures Reduction of …

Death rates (8-10X reduction) Drug use Criminal activity HIV spread

Increase in … Employment Social stability Retention, medication compliance, and monitoring